The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
Version 2 2024-06-03, 12:50Version 2 2024-06-03, 12:50
Version 1 2023-06-19, 05:59Version 1 2023-06-19, 05:59
journal contribution
posted on 2024-06-03, 12:50authored byS Saya, P Chondros, A Abela, Cathy MihalopoulosCathy Mihalopoulos, ML Chatterton, J Gunn, TF Chen, TM Polasek, E Dettmann, R Brooks, M King, L Spencer, P Alphonse, S Milton, G Ramsay, Z Siviour, J Liew, P Ly, M Thoenig, R Seychell, F La Rocca, LB Hesson, N Mejias, T Sivertsen, MA Galea, C Bousman, J Emery
The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care